Education on Human Cellular Tissue Products (HCTPs).
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- VIVEX BIOLOGICS
- Filing UUID
- 9538c193-f26e-47a3-90d7-b904eb0c4c2a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561)
Literal federal measure citations: S. 2561
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.